Compare Amphastar Pharmaceuticals Inc (AMPH) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Dollar Tree, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Dollar Tree, Inc. trades at $124.99 (market cap $24.00B). The key difference: Dollar Tree, Inc. is far larger — about 29.1× Amphastar Pharmaceuticals Inc's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | DLTR | |
|---|---|---|
Market Cap | $826.08M | $24.00B |
Sector | Health | Health |
52-Week High | $30.81 | $141.21 |
52-Week Low | $16.87 | $85.04 |
Enterprise Value | $1.22B | $30.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Dollar Tree (DLTR) trades at $124.91, up 3.3% today, with a bullish technical signal and strong recent earnings beats. The company shows robust profitability with a 34.71% ROE and announced a $2.5 billion share repurchase authorization in July 2026. Revenue for 2025 was $17.58 billion, though net income was negative due to a significant tax charge, while 2026 projections indicate a return to profitability.
The outlook is positive with analyst consensus favoring Buy ratings and a $131 price target. Key opportunities include margin expansion and multi-price strategy gains, but risks involve consumer traffic softness and cost pressures from tariffs and fuel. The stock's valuation appears reasonable with a P/E of 20.05, supporting a measured bullish stance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
